Download PDF
Semin intervent Radiol 2010; 27(4): 412-421
DOI: 10.1055/s-0030-1267856
© Thieme Medical Publishers

Review of Currently Available GP IIb/IIIa Inhibitors and Their Role in Peripheral Vascular Interventions

P. Anondo Stangl1 , Sara Lewis1
  • 1Department of Radiology, Mount Sinai Medical Center, One Gustave L. Levy Place, New York
Further Information

Publication History

Publication Date:
19 November 2010 (online)

Also available at
    Permissions and Reprints

ABSTRACT

The glycoprotein IIb/IIIa (GP IIb/IIIa) antagonists are the most recent additions to the antiplatelet agents available to the interventional radiologist. The currently available GP IIb/IIIa antagonists are abciximab, eptifibatide, and tirofiban. These medications have demonstrated excellent safety and efficacy in the setting of coronary arterial interventions. The fundamental benefit of the GP IIb/IIIa antagonists lies in their unique mechanism of action: the ability to prevent platelet aggregation, thrombus formation, and distal thromboembolism while preserving initial platelet binding to damaged vascular surfaces. A paucity of data exists regarding the role of GP IIb/IIIa inhibitors in peripheral vascular interventions. The GP IIb/IIIa antagonists would theoretically provide excellent antiplatelet therapy in patients undergoing any of a variety of endovascular interventions during which thrombosis or thromboembolism may endanger distal perfusion in patients with peripheral vascular disease. The goal of this summary is to review the indications for use, pharmacology, and evidence for efficacy of the GP IIb/IIIa antagonists in hopes of translating these data for application in the peripheral arterial circulation. Further research is necessary to determine how these agents may be safely used in combination with other anticoagulants or with stents, efficacy compared with standard regimens, success at preventing distal thromboembolism, and cost effectiveness.

KEYWORDS

Glycoprotein IIb/IIIa antagonist - peripheral vascular intervention - platelet aggregation - thromboembolism - anticoagulation

REFERENCES

  • 1 Coller B S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy.  Circulation. 1995;  92(9) 2373-2380
    CrossrefPubMedGoogle Scholar
  • 2 Hardisty R M, Dormandy K M, Hutton R A. Thrombasthenia: studies on three cases.  Br J Haematol. 1964;  10 371-387
    CrossrefPubMedGoogle Scholar
  • 3 Caen J P, Castaldi P A, Leclerc J C et al.. Congenital bleeding disorders with long bleeding time and normal platelet count: I. Glanzmann's thrombasthenia (report of fifteen patients).  Am J Med. 1966;  41 4-21
    CrossrefPubMedGoogle Scholar
  • 4 Shlansky-Goldberg R. Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries?.  J Vasc Interv Radiol. 2002;  13(3) 229-246
    CrossrefPubMedGoogle Scholar
  • 5 Awtry E H, Loscalzo J. Aspirin.  Circulation. 2000;  101(10) 1206-1218
    CrossrefPubMedGoogle Scholar
  • 6 Breddin H K. Antiplatelet agents in cardiovascular and cerebrovascular diseases.  Clin Appl Thromb Hemost. 1998;  4 87-95
    CrossrefPubMedGoogle Scholar
  • 7 Meadows T A, Bhatt D L. Clinical aspects of platelet inhibitors and thrombus formation.  Circ Res. 2007;  100(9) 1261-1275
    CrossrefPubMedGoogle Scholar
  • 8 Furman M I, Frelinger III A L, Michelson A D. GPIIb/IIIa inhibitor-induced dethrombosis.  J Thromb Thrombolysis. 2004;  18(1) 11-17
    CrossrefPubMedGoogle Scholar
  • 9 Gold H K, Garabedian H D, Dinsmore R E et al.. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.  Circulation. 1997;  95(7) 1755-1759
    CrossrefPubMedGoogle Scholar
  • 10 Coller B S. Platelets and thrombolytic therapy.  N Engl J Med. 1990;  322(1) 33-42
    CrossrefPubMedGoogle Scholar
  • 11 Smith Jr S C, Feldman T E, Hirshfeld Jr J W American College of Cardiology/American Heart Association Task Force on Practice Guidelines et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).  Circulation. 2006;  113(7) e166-e286
    CrossrefPubMedGoogle Scholar
  • 12 King III S B, Smith Jr S C, Hirshfeld Jr J W 2005 WRITING COMMITTEE MEMBERS et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Writing on Behalf of the 2005 Writing Committee.  Circulation. 2008;  117(2) 261-295
    CrossrefPubMedGoogle Scholar
  • 13 Cohen M. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.  Catheter Cardiovasc Interv. 2009;  74(4) 579-597
    CrossrefPubMedGoogle Scholar
  • 14 Topol E J, Califf R M, Weisman H F The EPIC Investigators et al.. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months.  Lancet. 1994;  343(8902) 881-886
    CrossrefPubMedGoogle Scholar
  • 15 The EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.  N Engl J Med. 1997;  336(24) 1689-1696
    CrossrefPubMedGoogle Scholar
  • 16 Tepe G, Schott U, Erley C M, Albes J, Claussen C D, Duda S H. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis.  AJR Am J Roentgenol. 1999;  172(5) 1343-1346
    PubMedGoogle Scholar
  • 17 Duda S H, Tepe G, Luz O et al.. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone—a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis.  Radiology. 2001;  221(3) 689-696
    CrossrefPubMedGoogle Scholar
  • 18 Drescher P, McGuckin J, Rilling W S, Crain M R. Catheter-directed thrombolytic therapy in peripheral artery occlusions: combining reteplase and abciximab.  AJR Am J Roentgenol. 2003;  180(5) 1385-1391
    PubMedGoogle Scholar
  • 19 Ouriel K, Castaneda F, McNamara T et al.. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.  J Vasc Interv Radiol. 2004;  15(3) 229-238
    CrossrefPubMedGoogle Scholar
  • 20 Tepe G, Hopfenzitz C, Dietz K et al.. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis—APART trial.  Radiology. 2006;  239(3) 892-900
    CrossrefPubMedGoogle Scholar
  • 21 Schweizer J, Kirch W, Koch R, Müller A, Hellner G, Forkmann L. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis.  Angiology. 2000;  51(11) 913-923
    CrossrefPubMedGoogle Scholar
  • 22 McNamara T O. Combination of ReoPro and Retevase in thrombolysis of peripheral arterial occlusion: preliminary results.  , (abstract) J Vasc Interv Radiol. 2001;  12(suppl) S123
    PubMedGoogle Scholar
  • 23 Drescher P, McGuckin J, Rilling W S, Crain M R. Catheter-directed thrombolytic therapy in peripheral artery occlusions: combining reteplase and abciximab.  AJR Am J Roentgenol. 2003 May;  180(5) 1385-1391
    PubMedGoogle Scholar
  • 24 Yoon H C, Miller Jr F J. Using a peptide inhibitor of the glycoprotein IIb/IIIa platelet receptor: initial experience in patients with acute peripheral arterial occlusions.  AJR Am J Roentgenol. 2002;  178(3) 617-622
    PubMedGoogle Scholar
  • 25 Burkart D J, Borsa J J, Anthony J P, Thurlo S R. Thrombolysis of acute peripheral arterial and venous occlusions with tenecteplase and eptifibatide: a pilot study.  J Vasc Interv Radiol. 2003;  14(6) 729-733
    PubMedGoogle Scholar
  • 26 Schweizer J, Kirch W, Koch R, Müller A, Hellner G, Forkmann L. Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis.  Angiology. 2003;  54(2) 155-161
    CrossrefPubMedGoogle Scholar
  • 27 Duda S H, Tepe G, Bala M et al.. Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusion.  Pharmacoeconomics. 2002;  20(3) 203-213
    CrossrefPubMedGoogle Scholar
  • 28 Dörffler-Melly J, Mahler F, Do D D, Triller J, Baumgartner I. Adjunctive abciximab improves patency and functional outcome in endovascular treatment of femoropopliteal occlusions: initial experience.  Radiology. 2005;  237(3) 1103-1109
    CrossrefPubMedGoogle Scholar
  • 29 Ansel G M, Silver M J, Botti Jr C F et al.. Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: a randomized trial.  Catheter Cardiovasc Interv. 2006;  67(2) 288-297
    CrossrefPubMedGoogle Scholar
  • 30 Feiring A J, Wesolowski A A, Lade S. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes.  J Am Coll Cardiol. 2004;  44(12) 2307-2314
    CrossrefPubMedGoogle Scholar
  • 31 Scarborough R M, Kleiman N S, Phillips D R. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?.  Circulation. 1999;  100(4) 437-444
    PubMedGoogle Scholar
  • 32 Kereiakes D J, Runyon J P, Broderick T M, Shimshak T M. IIb's are not IIb's.  Am J Cardiol. 2000;  85(8A, 8A) 23C-31C
    PubMedGoogle Scholar
  • 33 Mascelli M A, Lance E T, Damaraju L, Wagner C L, Weisman H F, Jordan R E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.  Circulation. 1998;  97(17) 1680-1688
    PubMedGoogle Scholar
  • 34 ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy . Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.  Lancet. 2000;  356(9247) 2037-2044
    CrossrefPubMedGoogle Scholar
  • 35 Schrör K, Weber A A. Comparative pharmacology of GP IIb/IIIa antagonists.  J Thromb Thrombolysis. 2003;  15(2) 71-80
    CrossrefPubMedGoogle Scholar
  • 36 Tcheng J E. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.  Am Heart J. 2000;  139(2 Pt 2) S38-S45
    CrossrefPubMedGoogle Scholar
  • 37 Memon M A, Blankenship J C, Wood G C, Frey C M, Menapace F J. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.  Am J Med. 2000;  109(3) 213-217
    CrossrefPubMedGoogle Scholar
  • 38 Kleiman N S, Tcheng J E. Safety issues surrounding use of platelet GPIIb/IIIa antagonists: reversibility and readministration.  Eur Heart J. 1999;  1(suppl E) E36-E42
    PubMedGoogle Scholar
  • 39 Nurden A T, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects.  Arterioscler Thromb Vasc Biol. 1999;  19(12) 2835-2840
    CrossrefPubMedGoogle Scholar
  • 40 Bougie D W, Wilker P R, Wuitschick E D et al.. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.  Blood. 2002;  100(6) 2071-2076
    PubMedGoogle Scholar
  • 41 Said S M, Hahn J, Schleyer E et al.. Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment.  Clin Res Cardiol. 2007;  96(2) 61-69
    CrossrefPubMedGoogle Scholar
  • 42 Keeley E C. Abciximab following clopidogrel reduces post-PCI complications in patients with acute coronary syndromes.  Nat Clin Pract Cardiovasc Med. 2006;  3(12) 650-651
    CrossrefPubMedGoogle Scholar
  • 43 Ellis S G, Tendera M, de Belder M A FINESSE Investigators et al. Facilitated PCI in patients with ST-elevation myocardial infarction.  N Engl J Med. 2008;  358(21) 2205-2217
    CrossrefPubMedGoogle Scholar
  • 44 Marmur J D, Mitre C A, Barnathan E, Cavusoglu E. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.  Am Heart J. 2006;  152(5) 876-881
    CrossrefPubMedGoogle Scholar
  • 45 Fischell T A, Attia T, Rane S, Salman W. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions.  J Invasive Cardiol. 2006;  18(10) 487-491
    PubMedGoogle Scholar
  • 46 Marmur J D, Poludasu S, Agarwal A et al.. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.  J Invasive Cardiol. 2006;  18(11) 521-526
    PubMedGoogle Scholar
  • 47 Kini A S, Chen V HT, Krishnan P et al.. Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.  Am Heart J. 2008;  156(3) 513-519
    CrossrefPubMedGoogle Scholar
  • 48 Fung A Y, Saw J, Starovoytov A et al.. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.  J Am Coll Cardiol. 2009;  53(10) 837-845
    CrossrefPubMedGoogle Scholar
  • 49 Valgimigli M, Bolognese L, Anselmi M et al.. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare metal stent implantation in patients with acute myocardial infarction: Design and rationale for the MULTI-STRATEGY trial.  Am Heart J. 2007;  154 39-45
    CrossrefPubMedGoogle Scholar
  • 50 Teirstein P S, Kao J, Watkins M et al.. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).  Am J Cardiol. 2005;  96(4) 500-505
    CrossrefPubMedGoogle Scholar

P. Anondo StanglM.D. 

Interventional Radiologist, Department of Vascular Therapy, Kaiser Permanente Colorado

2045 Franklin Street, Denver, CO 80205

Email: anondostangl@gmail.com

      >